Thus, pharmacological inhibition of IL-6R by tocilizumab shows selective toxicity to TNBC cells undergoing acute or chronic CIN, and selectively blocks the in vivo outgrowth of human and mouse TNBC cells with CIN. The gene discussed is IL6R; the disease is cervical squamous intraepithelial neoplasia.